COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

ABZYME RESEARCH FOUNDATION
NEW YORK, NY · EIN 273438658 · Form 990EZ · FY2025 · NTEE H81 · Medical Research · Small ($100K-$1M) · endhiv.com
revenue
$164K
expenses
$143K
net assets
$357K
employees
—
mission · from form 990

THE SUCCESSFUL COMPLETION OF THE PRE-INVESTIGATIONAL NEW DRUG MEETING WITH THE FDA AS WELLAS THE INITIATION OF A SCALE-UP OF THE MANUFACTURING OF THE VACCINE COMPOUND.

profile · synthesized from sources

The Abzyme Research Foundation is a nonprofit developing an electronically activated HIV vaccine (E-vaccine) to advance equitable global access to HIV therapy and prophylaxis. The organization owns the vaccine's intellectual property and funds research to advance clinical trials, with plans to license the vaccine royalty-free to manufacturers serving the Global South. Its mission emphasizes closing disparities in access by ensuring low-cost distribution in regions most affected by HIV.

named programs · 2 · from sources

What they call their work

Equitable Access Initiative
Planned licensing of the HIV vaccine royalty-free to manufacturers serving low- and middle-income countries, modeled after Gilead’s lenacapavir access plan.
HIV E-vaccine Development
Research and development of an electronically activated HIV vaccine to enable the body to break and destroy HIV, with ownership of all underlying intellectual property held by ARF.
activities · 1 group

What they do

  • Biomedical Research and Innovation 2 activities
    • Advance HIV vaccine candidate through preclinical and clinical development
      Conducts and supports research to advance an HIV vaccine candidate, including preclinical development activities such as optimizing vaccine design, conducting animal-model validation studies, and scaling up manufacturing. Collaborated with UC San Diego on atomic-resolution modeling to refine the E-vaccine structure and conducted validation studies in mice and non-human primates.
    • Secure intellectual property for HIV vaccine technologies
      Obtained intellectual property rights for the HIV E-vaccine and four additional related patents in 2025, establishing direct ownership of key scientific assets to support further development and potential commercialization.
financials · form 990EZ · fy2025
revenue
Total revenue$164K
Contributions & grants$164K100%
Program service revenue——
Investment income$10%
Other revenue—
expenses
Total expenses$143K
Program expenses—
Admin / overhead—
Fundraising—
Salaries & benefits—
Grants paid out—
balance sheet
Total assets$357K
Cash—
Investments—
Liabilities—
Net assets$357K
4 years on record · 2022–2025 · YoY revenue +1539.9%
leadership · form 990 part vii · fy2025

Who runs it

board members · 4
  • BETH MILLER SAKS — Director
  • TIM VOLK — Director
  • VALERIE KERR — Director
  • ZACHARY BARNETT — Director
relationships · 6

Who they work with

  • Amaro Lab Partner — Partnered with ARF to apply computational biology and AI-powered molecular dynamics for HIV vaccine design.
  • FDA Government — Engaged in pre-Investigational New Drug meeting regarding vaccine compound development.
  • Gilead Partner — Modeled HIV vaccine access plan after Gilead’s lenacapavir access plan.
  • Harvard Partner — Conducted HIV cure-research trials involving ARF's founder at labs including Bruce Walker's at Harvard.
  • Rockefeller University Partner — Conducted HIV cure-research trials involving ARF's founder at Michel Nussenzweig's lab at Rockefeller.
  • UC San Diego Partner — Collaborated with ARF to develop an atomic-resolution model of HIV's outer shell and optimize the E-vaccine structure using AI-powered molecular dynamics.
strategies · 4

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Atomic-Resolution Vaccine Design
    methodology: atomic-resolution vaccine design
    By using AI-powered molecular dynamics and atomic-resolution modeling to stabilize the neutralization-relevant conformation of HIV’s envelope protein, we produce more effective vaccine candidates because precise structural targeting enables stronger and more durable immune responses.
  • Equitable Access Licensing
    methodology: equitable_access_model
    By licensing the HIV vaccine royalty-free to manufacturers serving the Global South, we ensure broader access and faster scale-up in low-income regions because removing cost and intellectual property barriers accelerates production and distribution where need is greatest.
  • Equity-Centered Distribution Prioritization
    methodology: equity-centered_distribution
    By prioritizing low-cost deployment to populations in extreme poverty, we reduce AIDS-related mortality more effectively because targeting the most vulnerable populations produces greater health equity and public health impact.
  • Functional Cure Strategy
    methodology: functional cure strategy
    By designing vaccine-induced antibodies to both prevent HIV infection and reduce the latent viral reservoir, we advance toward a functional cure because dual-purpose immunogens simultaneously address transmission and persistence of the virus.